BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32618744)

  • 1. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
    Tymon-Rosario J; Zeybek B; Santin AD
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in antibody-drug conjugates for gynecologic malignancies.
    Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
    McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
    Ascione L; Crimini E; Trapani D; Marra A; Criscitiello C; Curigliano G
    Oncologist; 2023 Nov; 28(11):944-960. PubMed ID: 37665782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future potential targets of antibody-drug conjugates in breast cancer.
    Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
    Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
    Fenton MA; Tarantino P; Graff SL
    Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.
    Yang T; Li W; Huang T; Zhou J
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
    Nicolò E; Zagami P; Curigliano G
    Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
    Duro-Sánchez S; Nadal-Serrano M; Lalinde-Gutiérrez M; Arenas EJ; Bernadó Morales C; Morancho B; Escorihuela M; Pérez-Ramos S; Escrivá-de-Romaní S; Gandullo-Sánchez L; Pandiella A; Esteve-Codina A; Rodilla V; Dijcks FA; Dokter WHA; Cortés J; Saura C; Arribas J
    Cancer Res; 2022 Dec; 82(24):4670-4679. PubMed ID: 36222720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
    Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
    Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
    Abelman RO; Medford A; Spring L; Bardia A
    Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.